Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment

Several randomized, double blind, placebo-controlled trials (RCTs) have demonstrated that low-density lipoprotein cholesterol (LDL-C) lowering by using statins, including high-doses of strong statins, reduced the development of cardiovascular disease (CVD). However, among the eight RCTs which invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanai, Hidekatsu, Adachi, Hiroki, Hakoshima, Mariko, Katsuyama, Hisayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998547/
https://www.ncbi.nlm.nih.gov/pubmed/35408799
http://dx.doi.org/10.3390/ijms23073418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998547/
https://www.ncbi.nlm.nih.gov/pubmed/35408799
http://dx.doi.org/10.3390/ijms23073418

Ejemplares similares